

 Procedure- and drug-related health risks

Regenexx SD injectates provide a **non-surgical option** using injections of the patient's own stem cells from bone marrow concentrate (BMC).

^aAlong parameters of improving function, decreasing disability, or reducing re-tearing.

^bQALY = Cost-effectiveness analysis metric rating how well different types of medical treatments extend and/or improve patients' lives.

^cSimulated with a decision-analytical model.

^dTotal costs of Regenexx approach = direct costs of procedure using Regenexx injectates, braces, primary care physician, specialist visits, and post-procedure physical therapy. ^eTotal costs of RCR = direct costs of surgery, hospitalization, and

rehabilitation.

References

1. Boeren S, Abraham K, Frederix GWJ, van Lieshout C, van der Meulen MP. *Regenexx: The Next Generation of Orthopedic Recovery for Rotator Cuff Tears as an Alternative to Surgery.* Utrecht, NL: THINC Healthcare; 2023.

2. Yamamoto A, Takagishi K, Osawa T, et al. Prevalence and risk factors of a rotator cuff tear in the general population. *J Shoulder Elbow Surg.* 2010;19(1):116-120.

3. Colvin AC, Egorova N, Harrison AK, Moskowitz A, Flatow EL. National trends in rotator cuff repair. *J Bone Joint Surg Am.* 2012;94(3):227-233.

4. Iyengar JJ, Samagh SP, Schairer W, Singh G, Valone FH 3rd, Feeley BT. Current trends in rotator cuff repair: surgical technique, setting, and cost. *Arthroscopy*. 2014;30(3):284-288.

5. Karjalainen TV, Jain NB, Heikkinen J, Johnston RV, Page CM, Buchbinder R. Surgery for rotator cuff tears. *Cochrane Database Syst Rev.* 2019;12(12):CD013502.

 Nazari G, MacDermid JC, Bryant D, Athwal GS. The effectiveness of surgical vs conservative interventions on pain and function in patients with shoulder impingement syndrome. A systematic review and meta-analysis. *PLoS One*. 2019;14(5):e0216961.
Brindisino F, Salomon M, Giagio S, Pastore C, Innocenti T. Rotator cuff repair vs. nonoperative treatment: a systematic review with meta-analysis. *J Shoulder Elbow Surg*. 2021;30(11):2648-2659.
Haunschild ED, Gilat R, Lavoie-Gagne O, et al. Return to work after primary rotator cuff repair: a systematic review and meta-analysis. *Am J Sports Med*. 2021;49(8):2238-2247.

© Regenexx Corporate 2025. All rights reserved. 01/25.

THINC Cost-Effectiveness Report: The Regenexx Approach vs. Surgery for Rotator Cuff Tears



A healthcare innovation research institute that conducted the **first health technology assessment of its kind** evaluating cost-effectiveness and quality of life (QoL)^b

THINC Report Features

Compared cost-effectiveness

of injections that utilized BMC, which contains stem cells, with surgical RCR for rotator cuff tears in working-age adults

Calculated cost and QoL outcomes

for Regenexx approach and rotator cuff tear surgery^{b,d,e}

Analyzed data

from Regenexx approach clinical trials as well as surgical RCR cost-effectiveness analyses and clinical trials

THINC Report Key Findings

Compared with surgical RCR, procedures using Regenexx injectates demonstrated:

>**\$15,000** cost savings at 2 years

\$

(iii)

Minimal impact on QoL

60% lower total healthcare costs

THINC Report Conclusion:

The Regenexx approach offers a significantly cost-effective option for rotator cuff tear treatment.

Learn More

The THINC report calculated direct costs only in its analysis.

Physicians in the licensed Regenexx network sometimes use injections of the patient's platelet-rich plasma rather than injections of the patient's BMC, which contains stem cells, to treat rotator cuff tears when appropriate. The THINC report focused on BMC.